ACLX

Arcellx, Inc. (ACLX) | Rumor.io

Arcellx

ACLX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)99%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about ACLX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

May 5

Arcellx, Inc. (ACLX) director Jill Carroll sold 277,778 shares at $18.00, netting $5M, while CEO Elghandour and other directors sold shares in the trailing 12 months.
NovaRed Mining, a partner of ACLX, added 4,573.82 ha to its land package, bringing the total to 16,077.76 ha, with a strong exploration setup.
MetalCore, a tool used by NovaRed Mining, provides AI mineral prospectivity scores for land and real estate listings, with only 1,000 early spots available.

Generated by AI

Sentiment

Of the messages about ACLX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	95.59% +32.31
Bearish	—	—	0% 0	4.41% -32.31

Feb 25

Arcellx's ($ACLX) profitability is evident, with fully diluted EPS of $0.11 to $0.23 over the last 4 quarters.
The company's partnership with NeutronX has the potential to drive significant revenue, with a monthly flow of ~$7-8M, supporting a long-term price target of $0.89.
Arcellx's exclusive agreement with NeutronX, combined with a revenue history exceeding $73M, positions the company for multi-year contracts and a growth trajectory that could reach ~$96M, making a price target of $0.95 or higher reasonable.

Generated by AI

Topics

Of the messages about ACLX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	0%	0%	0%	4.67%
Macro	0%	0%	0%	0.49%
Earnings	0%	0%	0%	0.1%
Controversies	0%	0%	0%	1.43%
Announcements	100%	100%	100%	90.16%
Analysts	0%	0%	0%	3.15%

May 5

Arcellx, Inc. (ACLX) director Jill Carroll sold 277,778 shares at $18.00, a $5M transaction.
The company's insider ownership structure shows a net long position only held by the CFO.
The market may react to drilling outcomes rather than the company's expanding land packages and funding plans.

Generated by AI

Community

Of the messages about ACLX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	97.73%	45.21%
Newcomers	0%	0%	2.27%	54.79%

Regulars· Feb 23

Gilead Sciences (GILD) is acquiring Arcellx (ACLX) for $115 per share in cash, totaling $7.8 billion, with full control of anito-cel, a BCMA-directed CAR-T therapy for multiple myeloma.
The acquisition eliminates profit-sharing, milestones, and royalties, securing a $6 billion implied equity value tied to anito-cel sales.
The deal follows FDA acceptance of Arcellx's BLA for fourth-line relapsed/refractory multiple myeloma, with a decision date of December 23.

Newcomers· May 5

Arcellx, Inc. director Jill Carroll sold 277,778 shares at $18.00, reducing her net long position among insiders.
The company's latest feed appears older, and fresh quote checks are necessary to verify its current status.
MetalCore, a tool that provides AI mineral prospectivity scores, is offering early access to limited spots, including those for Arcellx, Inc. land parcels.

Generated by AI

Also Discussed

Investors talking about ACLX also mention

#	Name	Attention
1	JBT Marel CorporationJBTM	0.01%new
2	Legend Biotech Corporation ADRLEGN	0%+0
3	GRCL - Gracell Biotechnologies Inc.	——
4	SWTX - SpringWorks Therapeutics, Inc.	——
5	EHAB - Enhabit, Inc.	——
6	MKDWELL Tech Inc.MKDW	0%+0
7	LanzaTech Global Inc. Common StockLNZA	0%new
8	Janux Therapeutics, Inc.JANX	0%0
9	Distribution Solutions Group, Inc.DSGR	0%0
10	Global Business Travel Group, Inc.GBTG	0%new

Arcellx, Inc.

Location

Social

What share of all stock conversation is about ACLX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

May 5

Arcellx, Inc. (ACLX) director Jill Carroll sold 277,778 shares at $18.00, netting $5M, while CEO Elghandour and other directors sold shares in the trailing 12 months.
NovaRed Mining, a partner of ACLX, added 4,573.82 ha to its land package, bringing the total to 16,077.76 ha, with a strong exploration setup.
MetalCore, a tool used by NovaRed Mining, provides AI mineral prospectivity scores for land and real estate listings, with only 1,000 early spots available.

Generated by AI

Sentiment

Of the messages about ACLX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	95.59% +32.31
Bearish	—	—	0% 0	4.41% -32.31

Feb 25

Arcellx's ($ACLX) profitability is evident, with fully diluted EPS of $0.11 to $0.23 over the last 4 quarters.
The company's partnership with NeutronX has the potential to drive significant revenue, with a monthly flow of ~$7-8M, supporting a long-term price target of $0.89.
Arcellx's exclusive agreement with NeutronX, combined with a revenue history exceeding $73M, positions the company for multi-year contracts and a growth trajectory that could reach ~$96M, making a price target of $0.95 or higher reasonable.

Generated by AI

Topics

Of the messages about ACLX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	0%	0%	0%	4.67%
Macro	0%	0%	0%	0.49%
Earnings	0%	0%	0%	0.1%
Controversies	0%	0%	0%	1.43%
Announcements	100%	100%	100%	90.16%
Analysts	0%	0%	0%	3.15%

May 5

Arcellx, Inc. (ACLX) director Jill Carroll sold 277,778 shares at $18.00, a $5M transaction.
The company's insider ownership structure shows a net long position only held by the CFO.
The market may react to drilling outcomes rather than the company's expanding land packages and funding plans.

Generated by AI

Community

Of the messages about ACLX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	97.73%	45.21%
Newcomers	0%	0%	2.27%	54.79%

Regulars· Feb 23

Gilead Sciences (GILD) is acquiring Arcellx (ACLX) for $115 per share in cash, totaling $7.8 billion, with full control of anito-cel, a BCMA-directed CAR-T therapy for multiple myeloma.
The acquisition eliminates profit-sharing, milestones, and royalties, securing a $6 billion implied equity value tied to anito-cel sales.
The deal follows FDA acceptance of Arcellx's BLA for fourth-line relapsed/refractory multiple myeloma, with a decision date of December 23.

Newcomers· May 5

Arcellx, Inc. director Jill Carroll sold 277,778 shares at $18.00, reducing her net long position among insiders.
The company's latest feed appears older, and fresh quote checks are necessary to verify its current status.
MetalCore, a tool that provides AI mineral prospectivity scores, is offering early access to limited spots, including those for Arcellx, Inc. land parcels.

Generated by AI

Arcellx

Social

May 5

Sentiment

Feb 25

Topics

May 5

Community

Regulars· Feb 23

Newcomers· May 5

Also Discussed

Arcellx, Inc.

Company Information

Location

Also Discussed

Social

May 5

Sentiment

Feb 25

Topics

May 5

Community

Regulars· Feb 23

Newcomers· May 5